Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy.

Autor: Cabrera-Perez JS; Division of Allergy and Clinical Immunology, Brigham & Women's Hospital and Department of Medicine, Boston, Mass; Harvard Medical School, Boston, Mass., Carey VJ; Harvard Medical School, Boston, Mass; Channing Division of Network Medicine, Brigham & Women's Hospital and Department of Medicine, Boston, Mass., Odejide OO; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Mass; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Mass., Singh S; Department of Family Medicine and Community Health, Health Systems Science, Department of Medicine, UMass Chan Medical School, Worcester, Mass., Kupper TS; Harvard Medical School, Boston, Mass; Department of Dermatology, Brigham & Women's Hospital, Boston, Mass., Pillai SS; Harvard Medical School, Boston, Mass; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, Cambridge, Mass; Department of Medicine, Massachusetts General Hospital, Harvard, Cambridge, Mass., Weiss ST; Harvard Medical School, Boston, Mass; Channing Division of Network Medicine, Brigham & Women's Hospital and Department of Medicine, Boston, Mass., Akenroye A; Division of Allergy and Clinical Immunology, Brigham & Women's Hospital and Department of Medicine, Boston, Mass; Harvard Medical School, Boston, Mass; Channing Division of Network Medicine, Brigham & Women's Hospital and Department of Medicine, Boston, Mass. Electronic address: aakenroye@bwh.harvard.edu.

Publikováno v: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2024 Nov 07. Date of Electronic Publication: 2024 Nov 07.